These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26568546)

  • 1. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Schoppy DW; Sunwoo JB
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Treatment Options in Head and Neck Cancer.
    Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
    Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
    Busch CJ; Laban S; Knecht R; Hoffmann TK
    HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
    Bauman JE; Ferris RL
    Cancer; 2014 Mar; 120(5):624-32. PubMed ID: 24222079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising systemic immunotherapies in head and neck squamous cell carcinoma.
    Gildener-Leapman N; Ferris RL; Bauman JE
    Oral Oncol; 2013 Dec; 49(12):1089-96. PubMed ID: 24126223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy for HNSCC : Quo vadis?].
    Döscher J; Busch CJ; Schuler PJ; Laban S
    HNO; 2016 Oct; 64(10):700-7. PubMed ID: 27624904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
    Bowles DW; McDermott JD; Jimeno A
    Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
    von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
    Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Therapy in Head and Neck Cancers.
    Msaouel P; Massarelli E
    Cancer J; 2016; 22(2):108-16. PubMed ID: 27111906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in head and neck cancer: current practice and future possibilities.
    Agada FO; Alhamarneh O; Stafford ND; Greenman J
    J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
    Huang LL; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
    Schuler PJ; Doescher JC; Laban S; Hoffmann TK
    HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
    Bron L; Romero P
    Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
    Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
    HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.